Canada's health regulator has approved Novo Nordisk's weight loss drug Wegovy to reduce the risk of nonfatal heart attack or ...

When President-elect Donald Trump said Elon Musk and Vivek Ramaswamy would recommend major cuts to the federal government in ...

The stocks of companies that make the new class of drugs to treat obesity and manage diabetes were higher across the board ...

France said Wednesday that it 'intends to continue to work in close collaboration' with Israeli Prime Minister Benjamin Netanyahu despite an arrest warrant issued for him by the world’s top war crimes ...

Clinicians are advised to screen patients for conditions that would have rendered them ineligible to participate in the ...

The Biden administration plans to require Medicare and Medicaid to offer coverage of weight loss medications for people seeking obesity treatment.The new rule, which was proposed by the administration ...

About 42% of U.S. adults are obese, the CDC says. GLP-1 medications have changed the picture for people hoping to reduce ...

The Biden administration is proposing that Medicare and Medicaid pay for popular anti-obesity drugs for more Americans.

The White House said it's moving to make the federal health insurance plans pay for anti-obesity drugs such as Novo Nordisk's Wegovy and Eli Lilly's Zepbound for people who are obese, even if they don ...

The Biden administration proposed a rule to let Medicare and Medicaid cover obesity drugs like Ozempic. Millions would ...

Should employers, patients or insurers cover the $411 billion annual cost for GLP-1 drugs? U.S. healthcare industry grapples with this question as demand grows.

Investors are assessing the likelihood Trump will deliver on his threat to impose fresh tariffs on China, Canada and Mexico.